Fimasartan Achieving SBP Target (FAST) Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 369 participants.

Also called NCT02495324

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 369 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02495324
Other papers using this trial's data
  • Effect of Fimasartan versus Valsartan and Olmesartan on Office and Ambulatory Blood Pressure in Korean Patients with Mild-to-Moderate Essential Hypertension: A Randomized, Double-Blind, Active Control, Three-Parallel Group, Forced Titration, Multicenter, Phase IV Study (Fimasartan Achieving Systolic Blood Pressure Target (FAST) Study) Drug design, development and therapy, 2020 DOI, PubMed 32158190, PMC6986172 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02495324. Randomized; quadruple masking; primary purpose treatment. Start 2015-06 (actual); primary completion 2017-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Fimasartan Achieving SBP Target (FAST) Study
Acronym
FAST
Condition
Essential,Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
Fimasartan
Intervention (Drug)
Valsartan
Intervention (Drug)
Olmesartan medoxomil
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct02495324
Content hash
6e63f19ecad9b8c60b6d17cb9d5673130928e18cc66bb022ca1eebeb4ce1419c